Canagliflozin
- Generic Name
- Canagliflozin
- Brand Names
- Invokamet, Invokana
- Drug Type
- Small Molecule
- Chemical Formula
- C24H25FO5S
- CAS Number
- 842133-18-0
- Unique Ingredient Identifier
- 6S49DGR869
- Background
Canagliflozin, also known as Invokana, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise .
...
- Indication
This drug is used in conjunction with diet and exercise to increase glycemic control in adults diagnosed with type 2 diabetes mellitus .
...
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Major Adverse Cardiac Events, Type 2 Diabetes Mellitus, Doubling of serum creatinine
- Associated Therapies
- -
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-02-19
- Last Posted Date
- 2019-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 4401
- Registration Number
- NCT02065791
Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-09-11
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 171
- Registration Number
- NCT01939496
A Study to Compare the Pharmacodynamics of Canagliflozin and Dapagliflozin in Healthy Volunteers
- First Posted Date
- 2013-06-14
- Last Posted Date
- 2014-03-26
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 60
- Registration Number
- NCT01877889
A Study of the Effects of Canagliflozin on Plasma Volume in Patients With Type 2 Diabetes Mellitus
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-12-01
- Last Posted Date
- 2014-08-20
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 36
- Registration Number
- NCT01483781
A Study to Evaluate the Effects of Rifampin on Single-Dose Pharmacokinetics of Canagliflozin in Healthy Volunteers
- First Posted Date
- 2011-07-18
- Last Posted Date
- 2013-05-06
- Target Recruit Count
- 14
- Registration Number
- NCT01395927
The Effect of Food on the Administration of Canagliflozin in Healthy Adult Volunteers
- First Posted Date
- 2011-04-28
- Last Posted Date
- 2012-10-02
- Target Recruit Count
- 24
- Registration Number
- NCT01343290
A Study of Two Methods for Determining the Renal Threshold for Glucose in Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2011-01-10
- Last Posted Date
- 2013-04-22
- Target Recruit Count
- 28
- Registration Number
- NCT01273558
A Study of Canagliflozin in Study Participants With Various Degrees of Impaired Hepatic (Liver) Function
- First Posted Date
- 2010-08-23
- Last Posted Date
- 2013-05-29
- Target Recruit Count
- 24
- Registration Number
- NCT01186588
A Pharmacokinetic and Bioavailability Study of 28431754 (Canagliflozin) in Healthy Male Volunteers
- First Posted Date
- 2010-07-05
- Last Posted Date
- 2014-04-08
- Target Recruit Count
- 9
- Registration Number
- NCT01157000
The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-04-20
- Last Posted Date
- 2013-07-15
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 344
- Registration Number
- NCT01106690
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath